Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?

TY - JOUR

T1 - Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?

AU - Deutsch, E.

AU - Paragios, N.

N1 - Funding Information: The authors are partially supported from the Fondation ARC (SIGNIT201801286), the Fondation pour la Recherche Médicale (DIC20161236437) and Amazon Web Services (AWS). Funding Information: ED reports grants and personal fees from Roche Genentech, grants from Servier, grants from Astrazeneca, grants and personal fees from Merck Serono, grants from BMS, grants from MSD, outside the submitted work. NP is CEO and Founder of Therapanacea.

PY - 2019/6/1

Y1 - 2019/6/1

UR - http://www.scopus.com/inward/record.url?scp=85070953565&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz150

DO - 10.1093/annonc/mdz150

M3 - Editorial

C2 - 31124559

AN - SCOPUS:85070953565

SN - 0923-7534

VL - 30

SP - 879

EP - 881

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

M1 - mdz150

ER -